Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evalu...

Description complète

Détails bibliographiques
Auteurs principaux: Facchini, Gaetano, Caffo, Orazio, Ortega, Cinzia, D'Aniello, Carmine, Di Napoli, Marilena, Cecere, Sabrina C., Della Pepa, Chiara, Crispo, Anna, Maines, Francesca, Ruatta, Fiorella, Iovane, Gelsomina, Pisconti, Salvatore, Montella, Maurizio, Berretta, Massimiliano, Pignata, Sandro, Cavaliere, Carla
Format: Online Article Texte
Langue:English
Publié: Frontiers Media S.A. 2016
Sujets:
Pharmacology
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870277/
https://www.ncbi.nlm.nih.gov/pubmed/27242530
http://dx.doi.org/10.3389/fphar.2016.00123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870277/
https://www.ncbi.nlm.nih.gov/pubmed/27242530
http://dx.doi.org/10.3389/fphar.2016.00123

Documents similaires